ObsEva SA announced the appointment of chief financial officer, Timothy M. Adams. Mr. Adams is located in Boston, Massachusetts, where the company is currently hiring finance, IR and clinical operation people to support ObsEva's clinical-stage programs in uterine fibroids, endometriosis, Assisted Reproductive Technology and preterm labor. He has over 30 years of industry experience and most recently served as executive vice president and chief financial officer of Demandware Inc. Additionally Barbara Duncan, formerly of Intercept Pharmaceuticals Inc., has appointed company's board of directors as the chair of the Audit Committee. Ms. Duncan has 20 years of financial management experience in the industry and was previously the chief financial officer and treasurer at Intercept Pharmaceuticals Inc. The company is also announced that Frank Verwiel, M.D., who has served on the company's Board of Directors since early 2016, has been elected Chairperson of the Board.

Dr. Verwiel has over 25 years of experience across multiple operational, development and commercial disciplines for both small and large biotechnology and pharmaceutical companies. Prior to joining the ObsEva Board, he was President and Chief Executive Officer of Aptalis Pharma. He is currently a member of the Board of Directors of AveXis Inc., Achillion Pharma Inc. and Bavarian Nordic A/S.